Arteriovenous malformations (AVMs) result from abnormal development of blood vessels during fetal growth, creating direct connections between arteries and veins without capillaries. These tangles disrupt normal blood flow and increase the risk of hemorrhage, particularly in the brain and spinal cord.
AVMs form early in gestation, typically between weeks 6 and 12 of pregnancy, when blood vessel networks are establishing. They are not inherited in most cases, but certain genetic conditions can predispose individuals to their formation. The absence of capillary beds means high-pressure arterial blood flows directly into low-pressure veins, leading to vessel wall stress and rupture risk.
While most AVMs appear sporadically, research identifies specific genes linked to vascular development that, when mutated, may contribute to AVM formation. The most well-documented condition is hereditary hemorrhagic telangiectasia (HHT), caused by mutations in ENG, ACVRL1, or SMAD4 genes. People with HHT have a higher incidence of AVMs in the lungs, liver, and brain.
AVMs originate during embryogenesis when endothelial cells fail to properly organize into hierarchical vascular structures. Instead of forming a network of arteries → capillaries → veins, malformed vessels connect directly. This defect occurs during the angiogenic phase, when blood vessels sprout from existing ones.
Studies using mouse models show that disruption of signaling pathways such as Notch and VEGF leads to defective vessel maturation. In humans, exposure to teratogens-substances that interfere with fetal development-during early pregnancy may increase AVM risk, though evidence remains limited.
A 2021 study published in *Nature Neuroscience* tracked vascular development in human fetuses using postmortem imaging. Researchers found that AVMs were present in 1 in 1,200 fetuses examined, with no clear maternal health factor associated. This supports the idea that AVMs are largely developmental anomalies rather than acquired conditions.
While most AVMs occur in isolation, several syndromes are strongly linked to their presence. Hereditary hemorrhagic telangiectasia (HHT), also known as Osler-Weber-Rendu syndrome, affects approximately 1 in 5,000 people. About 20% of HHT patients develop cerebral AVMs, often detected incidentally during MRI scans for unrelated symptoms.
Another condition, PHACE syndrome, involves posterior fossa brain malformations, facial hemangiomas, and AVMs. Children with PHACE often have AVMs in the posterior circulation of the brain. Diagnosis requires imaging and clinical evaluation, with treatment focused on preventing hemorrhage.
Table: Common Genetic Conditions Associated with AVMs
| Syndrome | Gene(s) Involved | AVM Prevalence | Common Locations |
|---|---|---|---|
| HHT (Type 1) | ENG | ~20% of patients | Brain, lungs, liver |
| HHT (Type 2) | ACVRL1 | ~15% of patients | Brain, skin, mucosa |
| PHACE | Not fully mapped | High in affected infants | Posterior brain, neck |
These associations show that while most AVMs are sporadic, genetic screening may be warranted in families with multiple cases or known syndromes.
Unlike strokes or aneurysms, which can be influenced by lifestyle factors, AVMs are not caused by hypertension, smoking, or diet. There is no evidence that trauma or infections trigger AVM formation after birth.
However, radiation exposure during childhood may increase the risk of vascular malformations later in life. A 2019 retrospective analysis of pediatric cancer survivors treated with cranial irradiation found a 3.2-fold increased incidence of AVMs compared to controls. The risk rose with dose-those receiving over 20 Gy had a higher rate of late-onset AVMs.
Despite this, most AVMs are not related to prior radiation. Most cases are discovered in young adults or children, often during evaluation for seizures or headaches. A 2020 study in *Stroke* reported that 68% of cerebral AVMs were diagnosed in individuals under age 40, with no identifiable external cause.
Many assume AVMs are tumors or grow over time. This is incorrect. AVMs are structural defects present from birth and do not "develop" later in life. They remain stable in size for decades unless ruptured.
Another misconception is that AVMs always cause symptoms. In reality, up to 60% of cerebral AVMs are asymptomatic and discovered incidentally during imaging for unrelated reasons. Only about 10-15% of AVMs bleed annually, but when they do, the consequences can be severe.
One non-obvious fact: AVMs in the spinal cord are more likely to be symptomatic than those in the brain. Spinal AVMs often present with progressive weakness, numbness, or bladder dysfunction due to compression of neural tissue. Brain AVMs, by contrast, frequently go unnoticed until hemorrhage.
In 2018, a 29-year-old woman presented with sudden onset of left-sided weakness and slurred speech. An MRI revealed a 2.5 cm AVM in the right frontal lobe, with surrounding microhemorrhages. She had no family history of vascular disorders and no prior medical issues.
Further testing showed no mutation in ENG or ACVRL1. The AVM was classified as Spetzler-Martin Grade II, indicating moderate surgical risk. After embolization and Gamma Knife radiosurgery, follow-up imaging at 18 months showed complete obliteration of the lesion. She returned to work without neurological deficits.
This case illustrates that AVMs can appear unexpectedly in otherwise healthy individuals. The absence of known risk factors underscores that many cases stem from random developmental errors.
AVMs are often silent until they bleed. Symptoms include sudden headache, seizure, focal neurological deficits, or vision changes. If a person experiences a thunderclap headache-described as the worst headache of their life-imaging should be performed immediately.
For individuals with a known genetic condition like HHT, regular screening with MRI or MRA is recommended. The American Heart Association advises baseline brain imaging for HHT patients starting at age 10, with follow-ups every 5 years unless symptomatic.